Physicians at SSM Health Cardinal Glennon are using genetic profiling for individual treatment of leukemia for better response to a child’s specific case. Focusing on the whole child, the provider has embraced advanced clinical trials to offer children with leukemia the full benefit of advances in therapies.
Once example is the use of BLINCYTO (blinatumomab), a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. Blinatumomab, an immunologic therapy, was first approved by the Food and Drug Administration (FDA) in 2014, reports Fox2 Now St. Louis.
SSM Health Cardinal Glennon Children’s Hospital now uses this therapy not only in both relapsed pre-B acute lymphoblastic leukemia (the most common childhood cancer), but in addition, in clinical trials in some select patients as an initial therapy. The study is managed through the Children’s Oncology Group, an international cooperative organization targeting the advancement of pediatric cancer treatment.
About SSM Health Cardinal Glennon
SSM Health Cardinal Glennon is a leading academic medical center, with a Level I Pediatric Trauma Center and Level IV NICU, SSM Health Cardinal Glennon Children’s Hospital is a not-for-profit hospital staffed by the SLUCare Physician Group of Saint Louis University School of Medicine providing pediatric care to communities throughout Illinois, Missouri and beyond. At SSM Health Cardinal Glennon, they care for children and offer services beyond that support the overall well-being of our patients. They are committed not only to healing children today, but finding new ways to help them stay healthy in the future. SSM Health Cardinal Glennon Children’s Hospital has been designated a Magnet® Hospital by ANCC.
About Children’s Oncology Group
Founded in 2000, the Children’s Oncology Group, a clinical trials group supported by the National Cancer Institute (NCI), is the world’s largest organization devoted exclusively to pediatric cancer research. They conduct a spectrum of clinical research and translational research for infants, children, adolescents and young adults with cancer.
Almost all centers that treat children with cancer in the U.S. and Canada are part of the COG with more than 200 centers in America, Canada, Switzerland, Australia, and New Zealand. The member institutions have multidisciplinary teams consisting of physicians, research scientists, nurses, psychologists, pharmacists and other specialists.
The group involves more than 7,500 experts worldwide and nearly 100 active clinical-translational trials open at any given time. These trials include treatment for many types of childhood cancers, studies aimed at determining the underlying biology of these diseases, and trials involving new and emerging treatments, supportive care, and survivorship. Over 90% of 13,500 children and adolescents diagnosed with cancer each year in the United States are care for Children’s Oncology Group member institutions.
Call to Action: Should there be a loved one diagnosed with leukemia in Missouri see the link to Cardinal Glennon pediatric cancer treatment information.